- Home
- ZURA vs ADAP Comparison
ZURA vs ADAP Comparison
Compare ZURA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- ADAP
- Stock Information
- Founded
- ZURA 2022
- ADAP 2008
- Country
- ZURA United States
- ADAP United Kingdom
- Employees
- ZURA N/A
- ADAP N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- ZURA Health Care
- ADAP Health Care
- Exchange
- ZURA Nasdaq
- ADAP Nasdaq
- Market Cap
- ZURA 69.9M
- ADAP 75.5M
- IPO Year
- ZURA N/A
- ADAP 2015
- Fundamental
- Price
- ZURA $1.31
- ADAP $0.27
- Analyst Decision
- ZURA Buy
- ADAP Buy
- Analyst Count
- ZURA 7
- ADAP 6
- Target Price
- ZURA $14.33
- ADAP $1.35
- AVG Volume (30 Days)
- ZURA 708.2K
- ADAP 644.7K
- Earning Date
- ZURA 08-08-2025
- ADAP 08-11-2025
- Dividend Yield
- ZURA N/A
- ADAP N/A
- EPS Growth
- ZURA N/A
- ADAP N/A
- EPS
- ZURA N/A
- ADAP N/A
- Revenue
- ZURA N/A
- ADAP $179,639,000.00
- Revenue This Year
- ZURA N/A
- ADAP N/A
- Revenue Next Year
- ZURA N/A
- ADAP $35.48
- P/E Ratio
- ZURA N/A
- ADAP N/A
- Revenue Growth
- ZURA N/A
- ADAP 878.53
- 52 Week Low
- ZURA $0.97
- ADAP $0.20
- 52 Week High
- ZURA $5.07
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- ZURA 59.63
- ADAP 56.59
- Support Level
- ZURA $1.00
- ADAP $0.23
- Resistance Level
- ZURA $1.45
- ADAP $0.28
- Average True Range (ATR)
- ZURA 0.10
- ADAP 0.02
- MACD
- ZURA 0.03
- ADAP 0.00
- Stochastic Oscillator
- ZURA 68.89
- ADAP 87.96
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.